Home › Dermatitis › Texas
Pag-aaral pangklinika para sa Dermatitis sa Texas
6 pag-aaral para sa Dermatitis ang naghahanap ng mga kalahok sa mga site sa Texas.
Mga Lungsod sa Texas
Opisyal na teksto ng pag-aaral (English)
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
- Derm Texas, Dallas
- Stryde Research-Epiphany Dermatology, Southlake
Nagre-recruitPhase 3
Edad 12 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07765888First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Texas Dermatology and Laser Specialists, San Antonio
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07527923A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
- Arlington Research Center, Arlington
- Dermatology Treatment and Research Center, Dallas
- Derm Texas, Dallas
- at 2 pa
Nagre-recruitPhase 3
Edad 12 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07783425Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Arlington
- Novartis Investigative Site, Cypress
- Novartis Investigative Site, Dallas
- at 2 pa
Nagre-recruitPhase 2
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06947993A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Progressive Clinical Research, PA, San Antonio
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07599813A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 8, Southlake
Nagre-recruitPhase 2
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT07037901Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.